Vedere Bio

Vedere Bio is a privately held, emerging biopharmaceutical company discovering and developing next generation ocular gene therapies to make vision restoration a reality. Vedere is developing a pipeline of novel vision restoration and preservation therapies that will bring life-changing technology to a global unmet medical need. In 2020 Novartis acquired Vedere Bio Inc., leading to the formation of Vedere Bio II to continue pursuing next generation ocular gene therapies for vision restoration.

Headquarters Cambridge, MA
Pipeline Status Preclinical
Twitter @VedereBio
LinkedIn Vedere Bio